Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure
Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants increase the
risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI) …
risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI) …
Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in …
RS Milne, RA Silverman, IA Beck, J Mckernan-Mullin… - Aids, 2019 - journals.lww.com
Objectives: Among women initiating first-line nonnucleoside reverse-transcriptase inhibitor
(NNRTI)-based-ART with and without a history of single-dose nevirapine (sdNVP) with or …
(NNRTI)-based-ART with and without a history of single-dose nevirapine (sdNVP) with or …
[HTML][HTML] First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV …
F Zu Knyphausen, R Scheufele, C Kücherer, K Jansen… - PloS one, 2014 - journals.plos.org
Background Transmission of drug-resistant HIV-1 (TDR) can impair the virologic response to
antiretroviral combination therapy. Aim of the study was to assess the impact of TDR on …
antiretroviral combination therapy. Aim of the study was to assess the impact of TDR on …
[HTML][HTML] Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
ME Abram, RR Ram, NA Margot, TL Barnes, KL White… - PloS one, 2017 - journals.plos.org
T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor
(INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the …
(INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the …
Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment …
JD Baxter, D Dunn, A Tostevin, RL Marvig… - HIV …, 2021 - Wiley Online Library
Objectives The aim of this analysis was to characterize transmitted drug resistance (TDR) in
Strategic Timing of Antiretroviral Treatment (START) study participants by next‐generation …
Strategic Timing of Antiretroviral Treatment (START) study participants by next‐generation …
[HTML][HTML] HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high
Background The World Health Organization (WHO) has recommended guidelines for a HIV
drug resistance (HIVDR) survey for resource-limited countries. Eligibility criteria for patients …
drug resistance (HIVDR) survey for resource-limited countries. Eligibility criteria for patients …
[HTML][HTML] Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects
Objective To explore the potential of deep HIV-1 sequencing for adding clinically relevant
information relative to viral population sequencing in heavily pre-treated HIV-1-infected …
information relative to viral population sequencing in heavily pre-treated HIV-1-infected …
Promises and pitfalls of Illumina sequencing for HIV resistance genotyping
Abstract Genetic sequencing (“genotyping”) plays a critical role in the modern clinical
management of HIV infection. This virus evolves rapidly within patients because of its error …
management of HIV infection. This virus evolves rapidly within patients because of its error …
Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing …
KJ Metzner, P Rauch, V von Wyl… - The Journal of …, 2010 - academic.oup.com
Background. Selection of preexisting minority variants of drug-resistant human
immunodeficiency virus type 1 (HIV-1) can lead to virological failure in patients who receive …
immunodeficiency virus type 1 (HIV-1) can lead to virological failure in patients who receive …
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active …
AM Geretti, ZV Fox, CL Booth, CJ Smith… - JAIDS Journal of …, 2009 - journals.lww.com
Background: There are conflicting data on the impact of low-frequency transmitted drug-
resistant mutants on responses to first-line highly active antiretroviral therapy (HAART) …
resistant mutants on responses to first-line highly active antiretroviral therapy (HAART) …